VANCOUVER, BC – (January 25, 2018) – Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the “Company”) is pleased to report on the development of its Breathtec Disease Detection Breathalyzer (“V2”) prototype based on the FAIMS (field asymmetric waveform ion mobility spectrometry) technology. In collaboration with Cannabix Technologies (CSE:BLO), the V2 prototype is now complete. The new device, classified as “V3” is designed to operate both independently with its own self-contained FAIMS detector, or coupled in tandem directly to a triple-quadrupole Mass Spectrometer (MS) device. The device also incorporates several technological enhancements, including a modular design for faster iterative development, as well as size reduction into a compact Point-of-Care (POC) design.
Preliminary bench testing indicates a direct correlation between the V3 device and the MS. The MS is considered the gold standard in biomarker detection and it is anticipated that any results from a breathalyzer for disease detection will have to be independently verified by MS.
The Company plans to further develop the V3 device and implement findings from ongoing research conducted on biomarkers found in the breath that are associated with diseases, and continue on the path of developing hand-held Breathtec Disease Detection Breathalyzers to be non-invasive and highly accurate detection methods for various diseases.
CTO Mike Costanzo states, “Breathtec Biomedical remains dedicated to the development of a highly sensitive breathalyzer for disease detection. With our collaboration with Cannabix and the Vancouver Technical Team, we can expedite the testing and analysis of biomarkers related to disease.”
Update on Management
Breathtec Biomedical is currently in advanced talks with candidates for CEO to lead Breathtec Biomedical and will make announcements as the company progresses in its evaluation of candidates.
ON BEHALF OF THE BOARD
Chief Financial Officer & Director
ABOUT BREATHTEC BIOMEDICAL INC.
Breathtec Biomedical, Inc. (“Breathtec”) was formed to propel innovative research in the area of airborne analysis as a medical screening tool. Our efforts are aimed at leading the development of commercially viable methods for the early screening of certain pathogens. Our primary avenue of investigation is focused on innovation and advances in the field of specialized mass spectrometry. For more information, visit www.breathtecbiomedical.com.
CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.